Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AstraZeneca

Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session

Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.

Benzinga

Revealed: the budget bonanza for UK’s best-paid bosses from Tory tax cut

Scrapping top rate of tax could save hundreds of thousands for some of the highest earners, analysis reveals

The Guardian - UK

Stock Market Sees More Pain; Dow Jones Down Another 600 Points

The stock market is seeing a sea of read as losses accumulate for the week. Pizza and fiber optic stocks show strength.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test

Ionis stock tumbled Friday after partner AstraZeneca decided against sending their high cholesterol treatment into Phase 3 testing.

Investors Business Daily

Hamilton Accies Community Trust in cash boost from global pharmaceutical firm

AstraZeneca is supporting the work the Trust does across the Lanarkshire community.

Daily Record

Top Financial Stories Tuesday, September 13: Elon Musk's Takeover Set To Get Twitter Shareholder Approval, Intel Slashes Mobileye IPO Valuation, Goldman Sachs To Layoff About 500 Jobs And More…

Wall Street Journal

Benzinga

Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia. Spectrum Pharmaceuticals shares traded as high as 3.17 percent, in a range of $1.21 to $1.30 on day volume of 6.8 million…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

Benzinga

AstraZeneca clears US regulatory hurdle for new cancer drug Imfinzi

The drug reduces the risk of death by 20% compared with chemotherapy alone

Evening Standard

Better COVID vaccines are on the way. What do they do? And what technology might we see in future?

Regulators in Australia and the United States last week approved Omicron-specific boosters, following approval in the United Kingdom in mid-August.

The Conversation

Viral claims are blaming a surge in excess deaths in Europe on vaccines. But experts say that's not the case

A jump in the number of deaths among children in Europe could be caused by numerous factors, experts said, but vaccines are not to blame.

ABC News

AstraZeneca hails heart disease breakthrough after patient trials

The company first developed the drug as a treatment for type-2 diabetes

Evening Standard

Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022

Upgrades

Benzinga

AstraZeneca boss uncertain if yearly Covid-19 boosters for healthy are good use of resources

The chief executive officer believes most of the vaccinated population now has a "foundation immunity against severe disease"

Wales Online

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

AstraZeneca boss unsure if annual Covid-19 boosters are good use of resources

Chief executive officer Pascal Soriot said he believes most of the vaccinated population has a ‘foundation immunity against severe disease’.

Daily Mirror

New Covid drug could protect 500,000 vulnerable Brits but Government refuses to fund it

Brave schoolboy Max Johnson said the Government should offer vital protection to hundreds of thousands of immuno-compromised people who, like him, could risk being killed by Covid-19

The Independent UK

FTSE 100 chief executive average pay jumps by 39% to £3.4m

“To see CEO pay rocketing to more than 100 times the average salary is sickening,” say union bosses

Daily Mirror

Princess Diana's bodyguard seen for first time in 5 years after surviving Paris car crash

Trevor Rees-Jones, Princess Diana’s former bodyguard and now head of security for AstraZeneca, was photographed outside a Morrisons store in Shropshire 25 years on from the fatal car crash

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures Fall As Market Retreat Gains Steam; Elon Musk Makes This FSD Move

Futures fell sharply as the market rally pulls back. Elon Musk will hike Tesla FSD prices. Warren Buffett stock Occidental Petroleum surged Friday.

The Guardian - AU

Morrison government failed to provide priority for at-risk groups in vaccine rollout, report says

National audit report on vaccine rollout found planning ‘was not timely’ and distribution to priority populations had not ‘met targets’

The Guardian - UK

No plans for UK to order more supplies of AstraZeneca Covid vaccine

JCVI says mRNA vaccines such as the Pfizer and Moderna jabs are the most effective for UK booster programme

Investors Business Daily

IBD Stock Of The Day AstraZeneca Stalls As Gilead Looks To Take Its Breast Cancer Market

AstraZeneca is the IBD Stock Of The Day amid growing enthusiasm for its cancer drug, Enhertu. But AZN stock hit resistance Monday.

Financial Times

How science is getting closer to a world without animal testing

New technology involving miniature human organs built in a lab is a step towards better treatments and ending a contentious practice

Benzinga

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

Tribune News Service

More than a half billion doses of COVID vaccine made in Baltimore dumped, congressional panel finds

BALTIMORE — The tally of wasted COVID-19 vaccine continues to climb at the troubled Emergent BioSolutions plant in East Baltimore and now exceeds a half billion doses, according to findings a congressional panel released Thursday on the manufacturer once central to the U.S. coronavirus pandemic response.

1 … 9 10 11 12

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.